Myelodysplastic syndromes: A guide to treatment with epoetin and colony- stimulating factors

BioDrugs

Volumn 10, Issue 2, 1998, Pages 97-109

  Geissler, R Georg ^a   Ganser, Arnold ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CYTOTOXIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; HEMOPOIETIC GROWTH FACTOR; HYDROXYUREA; INTERLEUKIN 3; RECOMBINANT ERYTHROPOIETIN; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; BONE PAIN; CANCER CHEMOTHERAPY; CLINICAL TRIAL; ERYTHEMA; ERYTHROCYTE TRANSFUSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MYELODYSPLASTIC SYNDROME; PHLEBITIS; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0031667220     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199810020-00002     Document Type: Review

References (140)

1. Prchal JT, Trockmorton DW, Carrol AJ, et al. A common progenitor for myeloid and lymphoid cells. Nature 1978; 274: 590-1
2. Bennett JM, Catovsky D, Daniel M, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-99
3. Delacretaz F, Schmidt PM, Piguel D, et al. Histopathology and myelodysplastic syndromes: the FAB classification (proposals) applied to bone marrow biopsy. Am J Clin Pathol 1987; 87: 180-9
4. Hirokawa M, Miura I, Miura AB. Two karyotypically unrelated clones with 5q- and 2Oq- in a primary myelodysplastic syndrome patient evolving into acute nonlymphocytic leukaemia. Int J Hematol 1995; 62: 121-5
5. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992; 82: 158-67
6. Williamson PJ, Kruger AR, Reynolds PJ, et al. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994; 87: 743-5
7. Ganser A, Hoelzer D. Clinical course of myelodysplastic syndromes. Hematol Oncol Clin North Am 1992; 6: 607-18
8. Hoelzer D, Ganser A, Heimpel H. 'Atypical' leukemias: pre-leukemia, smoldering leukaemia and hypoplastic leukaemia. Recent Results Cancer Res 1984; 93: 69-101
9. Mufti GJ, Galton DAG. Myelodysplastic syndromes. Natural history and features of prognostic significance. Clin Haematol 1986; 15: 953-78
10. Boogaerts MA, Nelissen V, Roelant C, et al. Blood neutrophil function in primary myelodysplastic syndromes. Br J Haematol 1983; 55: 217-23
11. Jacobs A Genetic lesions in preleukemia. Leukaemia 1991; 5: 277-82
12. Van Lom K, Hagemeijer A, Smit E, et al. Cytogenetic clonality analysis in myelodysplastic syndrome: monosomy 7 can be demonstrated in the myeloid and in the lymphoid lineage. Leukaemia 1995; 9: 1818-21
13. Barnard DR, Kalousek DK, Wiersma SR, et al. Morphologic, immunologic, and cytogenetic classification of acute myeloid leukaemia and myelodysplastic syndrome in childhood: a report from the Children's Cancer Group. Leukaemia 1996; 10: 5-12
14. Kardos G, Veerman AJ, De Waal FC, et al. Familial sideroblastic anemia with emergence of monosomy 5 and myelodysplastic syndrome. Med Pediatr Oncol 1996; 26: 54-6
15. Kroef MJ, Jansen JH, Willemze R. et al. Detection of partial cDNA sequences differentially expressed in patients with myelodysplasia. Ann Hematol 1996; 72: 231-6
16. Bartram CR. Molecular genetic aspects of myelodysplastic syndromes. Hematol Oncol Clin North Am 1992; 6: 557-70
17. Gallagher A, Padua RA, Al Sabah A, et al. Aberrant expression of p21RAS but not p120GAP is a common feature in myelodysplasia. Leukaemia 1995; 9: 1833-40
18. Ganser A, Ottmunn OG, Schulz G, et al. Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine arabinoside in patients with myelodysplastic syndrome. A pilot study. Onkologie 1989; 12: 13-5
19. Ganser A, Seipelt G, Eder M, et al. Treatment of myelodysplastic syndromes with cytokines and cytotoxic drugs. Semin Oncol 1992; 19 Suppl. 4: 95-101
20. Ganser A, Heil G, Kolbe K, et al. Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukaemia - initial results. Ann Hematol 1993; 66: 123-5
21. Löffler H, Schmilz N, Gassmann W. Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Hematol Oncol Clin North Am 1992; 6: 619-32
22. Raquette RL, Koeffler HP. Differentiation therapy. Hematol Oncol Clin North Am 1992; 6: 687-706
23. Pogliani EM, Baldicchi L, Pioltelli P. et al. Idarubicin in combination with cytarabine and VP-16 in the treatment of post myelodysplastic syndrome acute myeloblastic leukaemia (MDS-AML). Leuk Lymphoma 1995; 19: 473-7
24. Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82: 677-81
25. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic hone marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14: 220-6
26. Ganser A, Hoelzer D. Treatment of myelodysplastic syndromes with hematopoietic growth factors. Hematol Oncol Clin North Am 1992, 6: 633-54
27. Dührsen U, Hossfeld D. Hematopoietic growth factors and the treatment of tumor-associated anemias. Ann Hematol 1994; 69: 213-21
28. Ganser A. Hematopoietic growth factors in the treatment of myelodysplastic syndromes. Curr Opin Hematol 1995; 2: 204-9
29. Legare RD, Gilliland DG. Myelodysplastic syndrome. Curr Opin Hematol 1995; 2: 283-92
30. Löwenberg B, Touw IP. Hematopoietic growth factors and their receptors in acute leukaemia. Blood 1993; 81: 281-92
31. Jacobs A, Janowska-Wieczorek A, Caro J, et al. Circulating erythropoietin in patients with myelodysplastic syndromes. Br J Haematol 1989; 73: 36-9
32. Bowen DT, Jacobs A, Cotes MP, et al. Serum erythropoietin and erythropoiesis in patients with myelodysplastic syndromes. Eur J Haematol 1990; 44: 30-2
33. Aul C, Arning M, Runde V, et al. Serum erythropoietin concentrations patients with myelodysplastic syndromes. Leuk Res 1991; 15: 571-5
34. Bowen D, Ehmer B, Neubert P, et al. The clearance of a single i.v. bolus of recombinant human erythropoietin from the serum of patients with myelodysplastic syndromes and its effects on erythropoiesis. Exp Hematol 1991; 19: 613-6
35. Hoefsloot LH, van Amelsvoort MP, Broeders CCAM, et al. Impaired erythropoiesis in myelodysplastic syndrome is associated with the inability of erythropoietin receptor to activate STAT-5 [abstract]. Blood 1995; 86 Suppl. 1: 271A
36. Di Raimondo F, Longo G, Cacciola FJR, et al. A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study. Eur J Haematol 1996; 56: 7-11
37. Ghio R, Balleari E, Ballestrero A, el al. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes. Acta Haematol 1993; 90: 58-64
38. Schouten HC, Vellenga E, van Rhenen DJ, et al. Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukaemia 1991; 5: 432-6
39. Van Kamp H, Tineke C, Prinsze-Postema TC, et al. Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia. Br J Haematol 1991; 78: 488-93
40. Bessho M, Jinnai I, Matsuda A, et al. Improvement of anemia by recombinant human erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. Int J Cell Cloning 1990; 8: 445-58
41. Oster W, Krumwieh D, Brune T, et al. Evaluation of erythropoietin (EPO) in the treatment of patients with myelodysplastic syndromes (MDS) - preclinical data supporting a rationale for sequential therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF) and EPO [abstract]. J Cancer Clin Oncol 1990; 116 Suppl.: 280
42. Stebler C, Ticheili A, Dazzi H, et al. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study. Exp Hematol 1990; 18: 1204-8
43. Bowen D, Culligan D, Jacobs A. The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. Br J Haematol 1991; 77: 419-23
44. Hellström E, Birgegard G, Locker D, et al. Treatment of myelodysplastic syndromes with recombinant human erythropoietin. Eur J Haematol 1991; 47: 355-60
45. Kurzrock R, Talpaz M, Estey E, et al. Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukaemia 1991; 5: 985-90
46. Laporte JPN, Isnard F, Fenaux P. Recombinant human erythropoietin at high dose is effective for the treatment of the anemia of myelodysplastic syndromes. Contrib Nephrol 1991; 88: 271-2
47. Stein RS, Abels RI, Krantz SB. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 1991; 78: 1658-63
48. Cazzola M, Ponchio L, Beguin Y, et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders: results of a phase I/II clinical trial. Blood 1992; 79: 29-37
49. Rafanelli D, Grossi A, Longo G, et al. Recombinant human erythropoietin for treatment of myelodysplastic syndromes. Leukaemia 1992; 6: 323-7
50. Razzano M, Caslini C, Cortellazzo S, et al. Therapy with human recombinant erythropoietin in patients with myelodysplastic syndromes. Br J Haematol 1992; 81: 628-30
51. Shepherd JD, Currie CJ, Sparling TG, et al. Erythropoietin therapy of myelodysplastic syndromes. Blood 1992; 79: 1891-2
52. Verhoef GE, Zachee P, Ferrant A, et al. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment. Ann Hematol 1992; 64: 16-21
53. Depaoli L, Levis A, Isabella N, et al. Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant-human-erythropoietin in myelodysplastic syndromes. Haematologica 1993; 78: 118-22
54. Goy A, Belanger C, Casadevall N, et al. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome. Br J Haematol 1993; 84: 232-7
55. Ludwig H, Fritz E, Leitgeb C, et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 1993; 4: 161-7
56. Mittelman M. Recombinant erythropoietin in myelodysplastic syndromes: whom to treat and how? More questions than answers. Acta Haematol 1993; 90: 53-7
57. Mohr B, Herrmann R, Huhn D. Recombinant human erythropoietin in patients with myelodysplastic syndromes and myelofibrosis. Acta Haematol 1993; 90: 65-70
58. Shapiro S, Gershon H, Rosenbaum H, et al. Characterization of circulating erythrocytes from myelodysplastic patients treated with recombinant human erythropoietin. Leukaemia 1993; 7: 1328-33
59. Spiriti MAA, Petti MC, Latagliata R, et al. Is recombinant human erythropoietin treatment in myelodysplastic syndromes worthwhile? Leuk Lymphoma 1993; 9: 79-83
60. Stenke L, Wallvik J, Celsing F, et al. Prediction of response to treatment with recombinant erythropoietin in myelodysplastic syndromes. Leukaemia 1993; 7: 1324-7
61. Urabe A, Mizoguchi H, Takaku F, et al. Phase II clinical study of recombinant erythropoietin on the anemia of myelodysplastic syndrome. Rinsho Ketsueki 1993; 4: 928-36
62. Yoshida Y, Anzai N, Kawabata H, et al. Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment. Ann Hematol 1993; 66: 175-80
63. Zeigler ZR, Jones D, Rosenfeld CS, et al. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome. Stem Cells 1993; 11: 49-55
64. Isnard F, Najman A, Jaur B, et al. Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes. Leuk Lymphoma 1994; 12: 307-14
65. Stone RM, Bernstein SH, Demetri G, et al. Treatment with recombinant human erythropoietin in patients with myelodysplastic syndromes. Leuk Res 1994; 18: 769-76
66. Rose EH, Abels RI, Nelson RA, et al. The use of r-HuEpo in the treatment of anemia related to myelodysplasia (MDS). Br J Haematol 1995; 89: 831-7
67. Stasi R, Brunetti M, Bussa S, et al. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clin Cancer Res 1997; 3: 733-9
68. Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89: 67-71
69. Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94: 288-99
70. Ganser A, Lindemann A, Seipelt G, et al. The effect of recombinant human interleukin-3 in patients with normal hemopoiesis and in patients with secondary bone marrow failure. Blood 1990; 76: 666-76
71. Dunbar CE, Smith D, Kimball J, et al. Sequential treatment with recombinant human growth factors to compare activity of GM-CSF and IL3 in the treatment of primary myelodysplasia [abstract]. Blood 1990; 76 Suppl. 1: 141a
72. Ganser A, Seipelt G, Lindemann A, et al. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 1990; 76: 455-62
73. Kurzrock R, Talpaz M, Estrov Z, et al. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 1991; 9: 1241-50
74. Bernstein SF, Gilliland DG, Aster J, et al. A randomized trial of two doses of recombinant interleukin-3 in patients with myelodysplastic syndrome [abstract]. Blood 1992; 80 Suppl. 1: 410a
75. Ganser A, Ottmann OG, Seipelt G, et al. Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. Leukaemia 1993; 7; 696-701
76. Nimer SD, Pacquette RL, Ireland P, et al. A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol 1994; 22: 875-80
77. Seipelt G, Ganser A, Duranceyk H, et al. Induction of TNF-α in patients with myelodysplastic syndromes undergoing treatment with interleukin-3. Br J Haematol 1993; 84: 749-51
78. Verhoef G, Demuynck H, Zachäe P, et al. Treatment of myelodysplastic syndromes (MDS) with the combination of interleukin-3 and erythropoietin [abstract]. Blood 1993; 82 Suppl. 1: 377a
79. Estey EH, Kurzrock R, Talpaz M, et al. Effects of low doses of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol 991; 77: 291-5
80. Rose C, Wattel E, Bastion Y, et al. Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 eases. Leukaemia 1994; 8: 1458-62
81. Schuster MW, Thompson JA, Larson R, et al. Randomized phase II study of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) in patients with neutropenia secondary to myelodysplastic syndrome (MDS) [abstract]. Blood 1995; 86 Suppl. 1: 338a
82. Antin JH, Smith BR, Holmes W, et al. Phase I/II study of recombinant human granulocyte macrophage colony stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 1988; 72: 705-13
83. Ganser A, Völkers B, Greher J, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes - a phase I/II trial. Blood 1989; 73: 31-7
84. Thompson JA, Douglas JL, Kidd P, et al. Subcutaneous granulocyte macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. J Clin Oncol 1989; 7: 629-37
85. Rosenfeld CS, Sulecki M, Evans C, et al. Comparison of intravenous versus subcutaneous recombinant human granulocyte macrophage colony-stimulating factor in patients with primary myelodysplasia. Exp Hematol 1991; 19: 273-7
86. Hoelzer D, Ganser A, Ottmann OG, et al. Effect of treatment with rhGM-CSF and low-dose cytosine arabinoside on leukemic blast cells in patients with myelodysplastic syndromes. Haematol Blood Transfus 1990; 33: 763-9
87. Herrmann F, Lindemann A, Klein H, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts. Leukaemia 1989; 3: 335-8
88. Willemze R, Visani G, de Witte Th, et al. A randomized phase I/II study with recombinant human GM-CSF in patients (pts) with myelodysplastic syndromes at a relatively low risk of developing acute leukaemia [abstract]. Blood 1990; 76 Suppl. 1: 337a
89. Gradishar WJ, LeBeau MM, O'Laughlin R, et al. Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia. Blood 1992; 80: 2463-70
90. Takahasha M, Yoshida Y, Kaku K, et al. Phase II study of recombinant human granulocyle-macrophage colony-stimulating factor in myelodysplastic syndrome and aplastic anemia. Acta Haematol 1993; 89: 189-94
91. Yoshida Y, Nakahata T, Shibata A, et al. Effects of long-term treatment with recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome. Leuk Lymphoma 1995; 18: 457-63
92. Kurzrock R, Talpaz M, Gomez JA, et al. Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients. Br J Haematol 1991; 78: 352-8
93. Delmer A, Karmochkine M, Cadiou M, et al. Recurrent spleen enlargement during cyclic granulocyte-macrophage colony-stimulaling factor therapy for myelodysplastic syndromes. Am J Hematol 1990; 34: 73-4
94. Vadhan-Raj S, Kellagher MJ, Keating M, et al. Phase I study of recombinant human granulocyte-macrophage colony stimulating factor in patients with myelodysplastic syndrome. N Engl J Med 1988; 317: 1545-52
95. Wilson PA, Ayscue LH, Jones GR, et al. Bone marrow histiocytic proliferation in association with colony-stimulating factor therapy. Am J Clin Pathol 1993; 99: 311-3
96. Maurer AB, Ganser A, Buhl R, et al. Restoration of impaired cytokine secretion from patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3. Leukaemia 1993; 7: 189-95
97. Bhalla K, Birkhofer M, Arlin Z, et al. Effect of recombinant GM-CSF and IL-3 on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukaemia 1988; 2: 810-3
98. Brach M, Klein H, Platzer E, et al. Effect of interleukin-3 on cytosine arabinoside-mediated cytotoxicity of leukemic myeloblasts. Exp Hematol 1990; 18: 748-53
99. Van der Lely N, De Witte T, Muus P, et al. Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells. Exp Hematol 1991; 19: 267-72
100. Höffken K, Overkamp F, Stirbu J, et al. Recombinant human granulocyte macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II study. Onkologie 1990; 13: 33-7
101. Gerhartz HH, Marcus R, Delmer A, et al. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukaemia. Leukaemia 1994; 8: 16-23
102. Cheson BD, Simon R. Low dose ara-C in acute nonlymphocytic leukaemia and myelodysplastic syndromes: a review of 20 years experience. Semin Oncol 1987; 14 Suppl. 1: 126-33
103. Rowe JM, Andersen J, Mazza J, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukaemia. A study of the Eastern Cooperative Oncology Group (E 1490). Blood 1995; 86: 457-62
104. Stone R, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukaemia. N Engl J Med 1995; 332: 1671-7
105. Delforge M, Demuynck H, Vandenberghe P, et al. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood 1995; 86: 3660-7
106. Negrin RS, Haeuber DH, Nagler A, et al. Maintenance therapy of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 1990; 76: 36-43
107. Kobayashi Y, Okabe T, Ozawa K, et al. Treatment of myelodysplastic syndromes with human granulocyte colony-stimulating factor: a preliminary report. Am J Med 1989; 86: 178-82
108. Negrin R, Haeuber DH, Nagler A, et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor A phase I/II trial. Ann Intern Med 1989; 110: 976-84
109. Yoshida Y, Hirashima K, Asano S, et al. Aphase II trial of recombinant human granulocyte colony-stimulating factor in the myelody splastic syndromes. Br J Haematol 1991; 78: 378-84
110. Ganser A, Seipelt G, Verbeeck W, et al. Effect of combination therapy with all-trans retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. Leukaemia 1994; 8: 369-75
111. Ohyashiki K, Ohyashiki JH, Toyama K, et al. Hematologic and cytogenetic findings in myelodysplastic syndromes treated with recombinant human granulocyte colony-stimulating factor. Jpn J Cancer Res 1989; 80: 848-54
112. Kaczmarski RS, Mufti GJ. Low-dose filgrastim therapy for chronic neutropenia. N Engl J Med 1993; 329: 1280-1
113. Yuo A, Kitagawa S, Okahe T, et al. Recombinant human granulocyte colony-stimulating factor repairs the abnormalities of neutrophils in patients with myelodysplastic syndromes and chronic myelogenous leukaemia. Blood 1987; 70: 404-11
114. Greenberg P, Negrin R, Nagler A, et al. Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. Int J Cell Cloning 1990; 8 Suppl 1: 293-302
115. Negrin RS, Stein R, Vardiman J, et al. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 1993; 82: 737-43
116. Greenberg P, Taylor K, Larson R, et al. Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS) [abstract]. Blood 1993; 82 Suppl. 1: 196a
117. Visani G, Cenacchi A, Tosi P, et al. All-trans retinoic acid improves erythropoiesis in myelodysplastic syndromes: a case report. Br J Haematol 1992; 81: 444-8
118. Aul C, Runde V, Gattermann N. All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. Blood 1993; 82: 1967-74
119. Kurzrock R, Estey E, Talpaz M. All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndromes. J Clin Oncol 1993: 11: 1489-96
120. Ohno R, Naoe T, Hirano M, et al. Treatment of myelodysplastic syndromes with all-trans retinoic acid. Blood 1993; 81: 1152-4
121. Maurer AB, Ganser A, Seipelt G, et al. Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haematopoietic growth factors. Br J Haematol 1995; 89: 449-56
122. Gordon MS, Nemunaitis J, Hoffman R, et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995; 85: 3066-76
123. Toyhama K, Toyhama Y, Nakayama T, et al. A novel factor-dependent human myelodysplastic cell line. MDS92, contains haemopoietic cells of several lineages. Br J Haematol 1995; 91: 795-9
124. Hellström-Lindberg E, Birgegard G, Carlsson MD, et al. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma 1993; 11: 221-8
125. Imamura M, Kobayashi M, Kobayashi S, et al. Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodysplastic syndromes. Ann Hematol 1994; 68: 163-6
126. Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996; 87: 4076-81
127. Ganser A, Maurer A, Contzen C, et al. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin, and α-tocopherol. Ann Hematol 1996; 72: 237-44
128. Hansen PB, Hippe E, Hellström-Lindberg E, et al. Recombinant human granulocyte macrophage colony-stimulating factor plus erythropoietin may improve anemia in selected patients with myelodysplasia. Am J Hematol 1993; 44: 229-36
129. List AL, Noyes W, Power J, et al. Combined treatment of myelodysplastic syndromes (MDS) with recombinant human interleukin-3 (IL-3) and erythropoietin (EPO) [abstract]. Blood 1993; 82 Suppl. 1: 377a
130. Nand S, Sosman J, Godwin JE, et al. A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. Blood 1994; 83: 357-60
131. Ganser A, Lindemann A, Ottmann OG, et al. Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis. Blood 1992; 79: 2583-91
132. Bernell P, Stenke L, Wallvik J, et al. A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anemia in myelodysplastic syndromes. Leuk Res 1996; 20: 693-9
133. Völkers B, Ganser A, Greher J, et al. Effect of tumor necrosis factor-alpha on human hematopoietic progenitor cells. Onkologie 1989; 12: 109-15
134. Verhoef G, Van Den Berghe H, Boogaerts M. Cytogenetic effects on cells derived from patients with myelodysplastic syndromes during treatment with hematopoietic growth factors. Leukaemia 1992; 6: 766-9
135. Ganser A, Janssen JWG, Ottmann OG, et al. In vivo effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on clonal and non-clonal cell populations in patients with clonal hematopoietic disorders. Leukaemia 1991; 5: 487-92
136. Anastasi J, Feng J, LeBeau MM, et al. Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy and clonal expansion. Blood 1993; 81: 1580-5
137. Vadhan-Raj S, Broxmeyer HE, Spitzer G, et al. Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome. Blood 1989; 74: 1491-8
138. Asano H, Ohashi H, Ichihara M, et al. Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes. Blood 1994; 84: 588-94
139. Glinsman-Gibson B, Spier C, Baier M, et al. Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodysplastic syndrome. Leukaemia 1994; 8: 827-32
140. Hellström-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997; 99: 344-51